A few weeks ago, Grant Ogren and Rhea Ashby-Durall, the executive director and the outreach manager of SAN (formerly Spokane AIDS Network), met with their representative from Gilead Sciences, the ...

Recent developments in antiretroviral therapy (ART) include longer-acting therapies that don't require a daily oral pill and two-drug regimens that could decrease toxicity associated with standard ...

Final data from LATITUDE study show switch to long-acting injectable treatment reduced the risk of virological failure by nearly half for study participants through 48 weeks, compared to those ...

Research presented at the International AIDS Society Conference on HIV Science in Kigali, Rwanda, included studies on 24-month clinical outcomes and participant-reported outcomes among adults with HIV ...

BOSTON — HIV can be suppressed when the long-acting combination of cabotegravir plus rilpivirine (Cabenuva, ViiV Healthcare) is administered every 8 weeks, according to data from the ATLAS-2M study, ...

Cabotegravir and rilpivirine (cabenuva), the only complete HIV treatment regimen delivered by injection, could be given by intramuscular injection to the thigh rather than the gluteal muscles, ...

Medically reviewed by Lindsay Cook, PharmD Key Takeaways Antiretroviral drugs help prevent HIV from replicating in the body.

Gilead Sciences, Inc. GILD announced upbeat results from an interim analysis of a second late-stage study evaluating the use of the company’s twice-yearly injectable HIV-1 capsid inhibitor, ...

Cabenuva (cabotegravir/rilpivirine) is a prescription drug used to treat HIV in certain people. Cabenuva comes as a liquid suspension that’s injected into a muscle ...